Skip to main content

Ipsogen Board OKs Acquisition by Qiagen

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – The board of directors of French companion diagnostics firm Ipsogen has approved the terms of a proposed acquisition by Qiagen.

Qiagen announced its plans to buy the firm in a deal valued at around €70 million ($101 million) a few weeks ago. At the time, Qiagen entered into exclusive negotiations with a group of Ipsogen shareholders to purchase about 47 percent of the company's outstanding shares currently held or controlled by company co-founders and board members. After the purchase agreement has been signed and the purchase is completed, Qiagen will begin to acquire all remaining shares of Ipsogen.

Qiagen is paying €12.90 per share to acquire a 47 percent stake in the company and to purchase all remaining shares afterward.

After the close of the market Friday, Qiagen said that Ipsogen's board had voted in favor of the deal and gave a favorable preliminary opinion on the subsequent public tender offer. Qiagen also entered into agreements with shareholders holding 61 percent of the share capital of Ipsogen to sell their shares to Qiagen.

As of June 12, Qiagen expects Ipsogen will become a fully consolidated subsidiary of the firm.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.